Dianthus Therapeutics (DNTH) Stifel 2024 Immunology and Inflammation Virtual Summit summary

Company overview and strategy

• Focuses on next-generation complement therapeutics, with lead candidate DNTH103 targeting activated C1s for selective classical pathway inhibition.

• DNTH103 designed for low-volume, infrequent, self-administered dosing, aiming for a patient-friendly profile.

• Three main indications: myasthenia gravis (MG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP).

• Recent competitor data in MMN and CIDP have de-risked these programs and validated the classical pathway approach.

• Raised $230 million in PIPE financing, extending cash runway to the second half of 2027.

Clinical development and trial design

• Phase 2 MG trial (MaGic) began in Q1 2024, with data expected in the second half of 2025.

• Phase 2 MMN trial (MoMentum) underway, with data expected in the second half of 2026.

• CIDP program design to be announced after FDA IND clearance, with data expected within current cash runway.

• MG trial uses two dose arms (300 mg and 600 mg every two weeks) plus placebo, mirroring prior successful designs.

• MMN trial runs dose-ranging in parallel for faster execution, closely following competitor trial structures.

Scientific rationale and differentiation

• Selective inhibition of activated C1s preserves lectin and alternative pathways, aiming for improved safety over terminal pathway inhibitors.

• DNTH103’s potency allows for lower dosing (300 mg every two weeks) compared to competitors, with strong pathway inhibition above IC90.

• Phase 1 data show consistent PK/PD, supporting confidence in dose selection for phase 2.

• Higher dose arm included in trials to confirm no additional efficacy is left untested.

• Differentiation from other C1s and C2 inhibitors centers on potency, dosing convenience, and targeted safety profile.